ATE554109T1 - Adenocarcinomspezifischer antikörper sam-6 und anwendungen dafür - Google Patents

Adenocarcinomspezifischer antikörper sam-6 und anwendungen dafür

Info

Publication number
ATE554109T1
ATE554109T1 AT04797921T AT04797921T ATE554109T1 AT E554109 T1 ATE554109 T1 AT E554109T1 AT 04797921 T AT04797921 T AT 04797921T AT 04797921 T AT04797921 T AT 04797921T AT E554109 T1 ATE554109 T1 AT E554109T1
Authority
AT
Austria
Prior art keywords
applications
specific antibody
antibody sam
sam
adenocarcinoma
Prior art date
Application number
AT04797921T
Other languages
English (en)
Inventor
Heinz Vollmers
Hans-Konrad Mueller-Hermelink
Original Assignee
Patrys Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patrys Ltd filed Critical Patrys Ltd
Application granted granted Critical
Publication of ATE554109T1 publication Critical patent/ATE554109T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04797921T 2003-11-14 2004-11-12 Adenocarcinomspezifischer antikörper sam-6 und anwendungen dafür ATE554109T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03026161A EP1531162A1 (de) 2003-11-14 2003-11-14 Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen
PCT/EP2004/012970 WO2005047332A1 (en) 2003-11-14 2004-11-12 Adenocarcinoma specific antibody sam-6, and uses thereof

Publications (1)

Publication Number Publication Date
ATE554109T1 true ATE554109T1 (de) 2012-05-15

Family

ID=34429369

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04797921T ATE554109T1 (de) 2003-11-14 2004-11-12 Adenocarcinomspezifischer antikörper sam-6 und anwendungen dafür

Country Status (7)

Country Link
US (2) US8163552B2 (de)
EP (3) EP1531162A1 (de)
JP (1) JP2008507951A (de)
AT (1) ATE554109T1 (de)
AU (1) AU2004289821B2 (de)
CA (1) CA2545454C (de)
WO (1) WO2005047332A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005351A2 (en) 2002-07-04 2004-01-15 Oncomab Gmbh Neoplasm specific antibodies and uses thereof
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
EP1531162A1 (de) 2003-11-14 2005-05-18 Heinz Vollmers Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
US20080199475A1 (en) * 2006-11-27 2008-08-21 Patrys Limited Novel glycosylated peptide target in neoplastic cells
WO2009104100A2 (en) * 2008-02-19 2009-08-27 Patrys Limited Antibody combinations, and methods of making and using same
US20110207917A1 (en) * 2009-02-09 2011-08-25 Patrys Limited Sam-6 variants, target and methods of use

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
DE3722647A1 (de) 1987-07-09 1989-01-19 Gerhard Ohlenschlaeger Galenische verwendung eines tripeptids als arzneimittel
DE4107154A1 (de) 1990-10-11 1992-04-16 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen melanom
AU662311B2 (en) 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
GB9105292D0 (en) 1991-03-13 1991-04-24 Sandoz Ltd Improvements in or relating to organic compounds
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5622701A (en) * 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US5639863A (en) * 1994-06-21 1997-06-17 Dan; Michael D. Human monoclonal antibodies specific to cell cycle independent glioma surface antigen
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US6140470A (en) 1995-06-30 2000-10-31 Yale University Human monoclonal anti-tumor antibodies
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
BR9712410A (pt) 1996-10-18 1999-10-19 Genentech Inc Anticorpo isolado, composição, ácido nucleico, vetor, célula hospedeira, método para fazer um anticorpo anti-erbb2, método para a determinação da presença de erbb2, kit, método paa a indução da morte celular e artigo manufaturado
JP2001511653A (ja) * 1997-05-15 2001-08-14 ジェネンテク，インコーポレイテッド Ａｐｏ−２レセプター
US6185924B1 (en) 1997-10-17 2001-02-13 Hitachi, Ltd. Gas turbine with turbine blade cooling
EP0927757A1 (de) 1997-12-03 1999-07-07 Leadd B.V. Verfahren und Mitteln um Apoptose zu induzieren durch Interferenz mit Bip-ähnliche Proteine
JP2002511259A (ja) * 1998-04-09 2002-04-16 ジェンセット ５’ｅｓｔおよびコードされるヒトタンパク質
US6846637B1 (en) 1998-06-18 2005-01-25 Imed Ab Fas peptides and antibodies for modulating apoptosis
CA2341276C (en) * 1998-08-28 2005-10-11 Genentech, Inc. Human anti-factor ix/ixa antibodies
GB9822115D0 (en) * 1998-10-09 1998-12-02 King S College London Treatment of inflammatory disease
PT1141019E (pt) 1998-12-22 2004-09-30 Heinz Peter Vollmers Fragmento da glicoproteina cd55/daf para a obtencao de medicamentos antitumorais com elevada eficacia assim como processo para a sua utilizacao
NZ592550A (en) 1999-03-25 2012-12-21 Abbott Gmbh & Co Kg Compostion comprising antibody capable of binding to p40 subunit of IL-12
US7049132B1 (en) * 1999-06-28 2006-05-23 University Of Southern California Stress-responsive induction of a therapeutic agent and methods of use
CA2589418A1 (en) * 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
US6677442B1 (en) * 1999-10-29 2004-01-13 University Of Kentucky Research Foundation Nucleic acid encoding human REV1 protein
AU3868001A (en) 2000-02-23 2001-09-03 Amgen Inc Antagonistic selective binding agents of osteoprotegerin binding protein
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7220840B2 (en) * 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
KR20120053525A (ko) 2000-06-16 2012-05-25 캠브리지 안티바디 테크놀로지 리미티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
CA2426710A1 (en) * 2000-11-08 2002-10-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US20030105003A1 (en) * 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
WO2002084277A1 (en) * 2001-04-17 2002-10-24 Abmaxis, Inc. Structure-based construction of human antibody library
EP1423425B1 (de) 2001-07-24 2010-12-01 Debiovision Inc. Rezeptor, dessen verwendung sowie mausantikörper
US20040048243A1 (en) * 2001-09-07 2004-03-11 Wadih Arap Methods and compositions for in vitro targeting
US7671010B2 (en) * 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
CA2468744C (en) 2001-12-03 2013-05-14 Alexion Pharmaceuticals, Inc. Hybrid antibodies
DE10210427A1 (de) * 2002-03-09 2003-10-09 Hans Konrad Mueller-Hermelink Humaner monoklonaler Antikörper
EP1572079A4 (de) 2002-03-29 2006-09-06 Centocor Inc Säugetier-cdr-mimetikörper, zusammensetzungen, verfahren und anwendungszwecke
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
DE10230516A1 (de) 2002-07-06 2004-01-15 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
WO2004005351A2 (en) 2002-07-04 2004-01-15 Oncomab Gmbh Neoplasm specific antibodies and uses thereof
CA2496938A1 (en) 2002-08-30 2004-03-11 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
SE0302312D0 (sv) * 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
WO2005001052A2 (en) 2003-06-06 2005-01-06 University Of Massachusetts Modulation of apoptosis
WO2005045428A2 (en) 2003-10-27 2005-05-19 University Of Southern California Methods and compositions for modulating apoptosis
US20070244304A1 (en) 2003-11-12 2007-10-18 Oncomab Gmbh Methods of Identifying Neoplasm-Specific Antibodies and Uses Thereof
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP1531162A1 (de) 2003-11-14 2005-05-18 Heinz Vollmers Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen
WO2005065418A2 (en) 2003-12-31 2005-07-21 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy
GB0404936D0 (en) 2004-03-04 2004-04-07 Univ London Screen
DE102004015179A1 (de) 2004-03-25 2005-10-13 Oncomab Gmbh Antigen des PM-2 Antikörpers und dessen Verwendung
US20080199475A1 (en) 2006-11-27 2008-08-21 Patrys Limited Novel glycosylated peptide target in neoplastic cells
US20110207917A1 (en) 2009-02-09 2011-08-25 Patrys Limited Sam-6 variants, target and methods of use

Also Published As

Publication number Publication date
EP2341077A1 (de) 2011-07-06
AU2004289821A1 (en) 2005-05-26
EP1709083B1 (de) 2012-04-18
EP1531162A1 (de) 2005-05-18
US20080108133A1 (en) 2008-05-08
WO2005047332A1 (en) 2005-05-26
US8163552B2 (en) 2012-04-24
CA2545454C (en) 2016-09-13
JP2008507951A (ja) 2008-03-21
AU2004289821B2 (en) 2011-10-06
CA2545454A1 (en) 2005-05-26
US8741296B2 (en) 2014-06-03
US20130039849A1 (en) 2013-02-14
EP1709083A1 (de) 2006-10-11

Similar Documents

Publication Publication Date Title
NL301089I2 (nl) imlifidase
DK1706424T3 (da) FC-region varianter
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
CY1116913T1 (el) Τροποποιημενα κλασματα fab αντισωματων
DK1718677T3 (da) Monovalente antistoffragmenter egnede som terapeutiske midler
ATE541857T1 (de) Optimierte fc-varianten und herstellungsverfahren dafür
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
ATE461220T1 (de) Anti-egfr-antikörper
CY1112507T1 (el) Μορια αντισωματος που εχουν ειδικοτητα για την ανθρωπινη ιl-1β
CY1114690T1 (el) Αντισωματα αντι-nrr notch1 και μεθοδοι χρησεις αυτων
BR0111125A (pt) Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos
NO20091976L (no) Nye forbindelser
ATE525392T1 (de) Regulatorische t-zellen-epitopen sowie zusammensetzungen damit und anwendungen davon
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
EP4105237A4 (de) Cldn18.2-antikörper und verwendung davon
EP1875237A4 (de) Docetaxel-immuntest
ATE357967T1 (de) Emulsionen mit oberflächenmodifizierten organischen molekülen
DE602004009824D1 (de) Analyse von massenspektraldaten in den ruhigen gebieten
ATE554109T1 (de) Adenocarcinomspezifischer antikörper sam-6 und anwendungen dafür
EA200601220A1 (ru) Анти-trkc антитела-агонисты и способы их применения
SE0301650D0 (sv) Novel compounds
ATE411300T1 (de) Neue cysteine protease hemmers und ihre therapeutische anwendungen
DK1771732T3 (da) Taxol-immunassay
ATE494307T1 (de) Neoplasma-spezifische antikörper und deren verwendungen
ATE527280T1 (de) Fluoreszentprotein und chromoprotein